利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

2 条记录 (耗时 0.01 秒)

    METHOD OF OPTIMIZING THE TREATMENT OF PHILADELPHIA-POSITIVE LEUKEMIA WITH IMATINIB MESYLATE
    1.
    发明公开
    METHOD OF OPTIMIZING THE TREATMENT OF PHILADELPHIA-POSITIVE LEUKEMIA WITH IMATINIB MESYLATE 审中-公开
    用于优化费城阳性白血病伊马替尼的治疗

    公开(公告)号：EP2370078A1

    公开(公告)日：2011-10-05

    申请号：EP09775407.1

    申请日：2009-11-30

    申请人： Novartis AG ,  Medvet Science Pty Ltd

    发明人： WANG, Yanfeng ,  KALEBIC, Thea ,  HUGHES, Timothy Peter ,  WHITE, Deborah

    IPC分类号： A61K31/506 ,  A61K35/02

    CPC分类号： A61K31/506

    摘要： The present invention relates to a method of treating Philadelphia-positive leukemia (Ph+ leukemia), in a particular chronic myeloid leukemia (CML), in a human patient population. More specifically, the present invention pertains to a method of treating Ph+ leukemia, such as CML or Ph+ ALL, in a human patient suffering from Ph+ leukemia comprising the steps of (a) administering a predetermined fixed amount of Imatinib as a free base or in the form of a pharmaceutically acceptable salt thereof to the human patient, (b) collecting at least one blood sample from the patient, e.g. within the first 12 months of treatment, (c) determining the plasma trough level (Cmin) of Imatinib, (d) determining the OCT-1 Activity in the blood sample, and (e) adjusting the dose of Imatinib applied to the individual patient in a manner that an Imatinib Cmin value is achieved in the patient of at least 800 ng/mL, if in step (c) an Imatinib Cmin value of less than 800 ng/mL is found and in step (d) an OCT-1 Activity is found below 6.0 to 10.0 ng/200,000 cells..

    METHOD FOR OPTIMIZING THE TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH ABL TYROSINE KINASE INHIBITORS
    2.
    发明公开
    METHOD FOR OPTIMIZING THE TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH ABL TYROSINE KINASE INHIBITORS 审中-公开
    用于优化治疗白血病WITH ABL慢性髓细胞性酪氨酸激酶抑制剂

    公开(公告)号：EP2170336A1

    公开(公告)日：2010-04-07

    申请号：EP08756991.9

    申请日：2008-06-20

    申请人： MEDVET SCIENCE PTY. LTD.

    发明人： HUGHES, Timothy Peter ,  WHITE, Deborah

    IPC分类号： A61K31/506 ,  A61P35/02 ,  G01N33/60

    CPC分类号： A61K31/506

    摘要： The present invention relates to a method for evaluating patients to help optimizing the treatment of chronic myeloid leukemia (CML) in a human patient population. More specifically, the method comprises the steps of (a) determining the OCT-1 Activity in pre-therapy blood of a warm-blooded animal suffering from CML, and (b) administering a daily dose between about 500 and 1200 mg of Imatinib mesylate to the warm-blooded animal suffering from CML showing an OCT-1 Activity corresponding to Imatinib intracellular concentration below about 6.0 to 10.0 ng/200,000 cells, especially about 8.0 to 8.5 ng/200,000 cells.